Title
Frontal Cortex Neuropathology in Dementia Pugilistica

Permalink
https://escholarship.org/uc/item/76w0875k

Journal
Journal of Neurotrauma, 29(6)

ISSN
1557-9042

Authors
Saing, Tommy
Dick, Malcolm
Nelson, Peter T.

Publication Date
2012-04-10

Peer reviewed
Frontal Cortex Neuropathology in Dementia Pugilistica

Tommy Saing,1 Malcolm Dick,1 Peter T. Nelson,4,6 Ronald C. Kim,1,2 David H. Cribbs,1,3 and Elizabeth Head1,3–5

Abstract
Dementia pugilistica (DP) is associated with chronic traumatic brain injury (CTBI), and leads to a “punch drunk” syndrome characterized by impairments in memory and executive function, behavioral changes, and motor signs. Microscopic features include the accumulation of neurofibrillary tangles (NFTs), beta-amyloid (Aβ), and TAR DNA binding protein 43 (TDP-43) pathology. Here we describe detailed clinical and neuropathological data about a 55-year-old retired boxer (ApoE3/4), who presented with executive dysfunction and behavioral impairments. At autopsy, significant Aβ pathology was seen, primarily in the form of diffuse plaques. Tau pathology was extensive and was determined to be of Braak and Braak stage VI. Frontal white matter showed evidence of glial tau inclusions (astrocytes and oligodendroglia). Cerebrovascular pathology was minimal with patchy amyloid angiopathy. Inflammation was another key feature, including microglial activation and significant C1q labeling of neurons, along with NFTs. TDP-43-positive pathology was also observed. Inflammation may be a key inciting as well as propagating feature of DP neuropathology.

Key words: beta-amyloid; C1q; chronic traumatic encephalopathy; tauopathy; TDP-43

Introduction
Dementia pugilistica (DP) is associated with repeated head trauma, resulting in a progressive disorder first described as “punch-drunk syndrome” in 1928 by Martland (Martland, 1928). Approximately 17% of retired professional boxers exhibit signs of cognitive dysfunction associated with chronic traumatic brain injury (CTBI), and more recently chronic traumatic encephalopathy (CTE), with severe dementia occurring in about 6% of subjects (Heilbronner et al., 2009; Roberts, 1969). DP is characterized by memory deficits, disorientation, confusion, and frontal signs such as loss of insight and inappropriate behaviors (Corsellis et al., 1973; Forstl et al., 2010; Gavett et al., 2011; Roberts, 1969). DP is characterized by memory deficits, disorientation, confusion, and frontal signs such as loss of insight and inappropriate behaviors (Corsellis et al., 1973; Forstl et al., 2010; Gavett et al., 2011; Roberts, 1969). Additional behavioral changes, such as irritability, aggression, disinhibition, euphoria, and impaired insight, have also been reported (Gavett et al., 2011; Mendez, 1995). Motor abnormalities such as ataxia, spasticity, impaired coordination, and parkinsonism (pugilistica parkinsonism) are also consistent features of the syndrome (Forstl et al., 2010; Gavett et al., 2011; Mendez, 1995). Interestingly, the clinical signs and progression of dementia in boxers may share features with other frontotemporal dementias (FTDs; Scully et al., 1999), although exceptions have been noted (Areza-Fegyveres et al., 2007).

The neuropathological features of DP have several consistent patterns across case reports (Corsellis, 1989; Gavett et al., 2011; Jordan, 2000; McKee et al., 2009; Nowak et al., 2009). These include an accumulation of neurofibrillary tangles (NFTs), and a lesser degree of beta-amyloid (Aβ) pathology (Allsop et al., 1990; Hof et al., 1992; Jordan et al., 1995; McKenzie et al., 1996; Nowak et al., 2009; Roberts, 1988; Scully et al., 1999; Tokuda et al., 1991). Another relatively consistent feature of DP is the presence of extracellular NFTs, with some studies showing Aβ-positive extracellular NFTs (Allsop et al., 1990; Hof et al., 1992; Schmidt et al., 2001; Tokuda et al., 1991). Recently, TAR DNA binding protein 43 (TDP-43) pathology has also been observed in DP (King et al., 2010), which is also a feature of other dementias (Wilson et al., 2011). Septal abnormalities (fenestration), widening of the lateral ventricles, and thinning of the fornix have both been observed at autopsy (Corsellis et al., 1973; Spillane, 1962), and in in vivo studies (Moseley, 2000; Scully et al., 1999; Spillane, 1962; Zhang et al., 2003,2006). Oftentimes there is scarring of the cerebellum and pronounced Purkinje cell loss (Corsellis et al., 1973). Significant loss of pigmented neurons in the substantia

---

1Institute for Memory Impairments and Neurological Disorders, and 2Department of Pathology, University of California–Irvine, Irvine, California.  
3Department of Neurology, 4Sanders-Brown Center on Aging, 5Department of Molecular and Biomedical Pharmacology, and 6Department of Pathology, University of Kentucky, Lexington, Kentucky.
nigra may cause extrapyramidal motor signs in affected subjects (Corsellis et al., 1973; Forstl et al., 2010). Basal forebrain cholinergic neurons are also affected (Uhl et al., 1982).

The purpose of the current study was to report on an interesting DP patient who was thoroughly evaluated clinically and neuropathologically. Although serious concussions can cause permanent neurologic damage, in boxing the acute neurologic injury is more often transient (Forstl et al., 2010; Gavett et al., 2011; Heilbronner et al., 2009). On the other hand, repetitive concussive and subconcussive blows to the brain over many years have been identified as the primary cause of neurologic symptoms, and can occur many years and even decades after the individual has retired from boxing. While the exact mechanisms involved in the significant long-term delayed sequelae associated with sports-related CTE are poorly understood (DeKosky et al., 2010), the clinical presentation is consistent with a slowly progressive tauopathy (McKee et al., 2011; Gavett et al., 2011; Heilbronner et al., 2009). On the other hand, neurologic injury is more often transient (Forstl et al., 2010; Heilbronner et al., 2009). Prussian blue histochecmistry was by previously published methods (Petrushina et al., 2007).

Results

DP patient clinical characteristics and neurological examination

On presentation, the patient was a right-handed, 47-year-old Caucasian male with 12 years of education with complaints of memory problems and personality changes. He was followed annually at the UCI-ADRC for a total of seven visits. He had been a professional lightweight to heavyweight boxer for 13 years. During his boxing career he was knocked out twice, once with amnesia lasting 3 days. According to his wife, memory problems were first observed when he was 32 years of age, approximately 1 year after he retired from boxing. Problems with increased forgetfulness were evidenced by difficulty completing tasks, an inability to follow instructions, and trouble holding a job. Problems with recent memory became progressively more noticeable over time, along with difficulties in attention, speed of thinking, and a variety of fronto-executive behaviors, including abstraction, judgment, planning, and organization. At his initial visit, personality changes, including frequent outbursts of anger, poor judgment, inability to tolerate frustration, and marked disinhibition, were the wife’s primary concerns. For example, he would make insensitive and inappropriate comments to strangers on the street. His affect was described as fluctuating between euphoric and flat or apathetic, but not depressed.

### Table 1. Case Demographic Data

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (y)</th>
<th>Sex</th>
<th>PMI (h)</th>
<th>Clinical diagnosis</th>
<th>Neopathology diagnosis</th>
<th>Cause of death</th>
<th>Brain weight (g)</th>
<th>B&amp;B Tangle stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>55</td>
<td>M</td>
<td>5.8</td>
<td>Possible AD, FTD,</td>
<td>AD</td>
<td>Dementia</td>
<td>1115.9</td>
<td>VI, A</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>F</td>
<td>5</td>
<td>Possible FTD</td>
<td>AD</td>
<td>Unknown</td>
<td>950</td>
<td>VI, C</td>
</tr>
<tr>
<td>3</td>
<td>56</td>
<td>F</td>
<td>3.9</td>
<td>Possible FTD</td>
<td>AD</td>
<td>Dementia</td>
<td>1004.3</td>
<td>VI, C</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>M</td>
<td>3.3</td>
<td>Possible AD</td>
<td>AD</td>
<td>Dementia</td>
<td>1211.6</td>
<td>VI, C</td>
</tr>
<tr>
<td>5</td>
<td>61</td>
<td>M</td>
<td>5.6</td>
<td>Possible AD</td>
<td>AD</td>
<td>Pneumonia</td>
<td>994.8</td>
<td>VI, C</td>
</tr>
<tr>
<td>6</td>
<td>61</td>
<td>M</td>
<td>14</td>
<td>Non-demented</td>
<td>Control</td>
<td>Pneumonia</td>
<td>1500</td>
<td>N/A</td>
</tr>
<tr>
<td>7</td>
<td>64</td>
<td>F</td>
<td>8</td>
<td>Non-demented</td>
<td>Control</td>
<td>Myocardial infarction</td>
<td>1182</td>
<td>N/A</td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>F</td>
<td>5</td>
<td>Non-demented</td>
<td>Control</td>
<td>Pulmonary</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

AD, Alzheimer’s disease; FTD, frontotemporal dementia; PMI, post mortem interval; B&B, Braak & Braak; N/A, not applicable.
Table 2. Antibodies Used in the Study

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Marker</th>
<th>Host</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1q</td>
<td>Classical complement pathway</td>
<td>Polyclonal</td>
<td>Dako, Carpinteria, CA</td>
</tr>
<tr>
<td>CD3</td>
<td>T lymphocytes</td>
<td>Monoclonal</td>
<td>Novocastra Laboratories, Ltd., Newcastle upon Tyne, U.K.</td>
</tr>
<tr>
<td>CD4</td>
<td>T lymphocytes</td>
<td>Monoclonal</td>
<td>Novocastra Laboratories, Ltd.</td>
</tr>
<tr>
<td>CD8</td>
<td>T lymphocytes</td>
<td>Monoclonal</td>
<td>Novocastra Laboratories, Ltd.</td>
</tr>
<tr>
<td>CD40</td>
<td>B cells</td>
<td>Monoclonal</td>
<td>Novocastra Laboratories, Ltd.</td>
</tr>
<tr>
<td>GFAP</td>
<td>Astrocytosis</td>
<td>Polyclonal</td>
<td>Dako</td>
</tr>
<tr>
<td>LN-3</td>
<td>Microglial activation</td>
<td>Monoclonal</td>
<td>ICN Biomedicals, Aurora, OH</td>
</tr>
<tr>
<td>CD68</td>
<td>Microglial activation</td>
<td>Monoclonal</td>
<td>Dako, Temcula, CA</td>
</tr>
<tr>
<td>6E10</td>
<td>Senile plaques</td>
<td>Monoclonal</td>
<td>Signet Laboratories, Dedham, MA</td>
</tr>
<tr>
<td>Anti-A42</td>
<td>Senile plaques</td>
<td>Polyclonal</td>
<td>Biosource International, Camarillo, CA</td>
</tr>
<tr>
<td>Anti-A40</td>
<td>Senile plaques</td>
<td>Polyclonal</td>
<td>Biosource International</td>
</tr>
<tr>
<td>22C11</td>
<td>APP N-terminus</td>
<td>Monoclonal</td>
<td>Chemicon International, Temecula, CA</td>
</tr>
<tr>
<td>AT8</td>
<td>Neurofibrillary tangles</td>
<td>Monoclonal</td>
<td>Pierce Biotechnology, Rockford, IL</td>
</tr>
<tr>
<td>MC-1</td>
<td>Early neurofibrillary tangles</td>
<td>Monoclonal</td>
<td>Peter Davies, Einstein, NY</td>
</tr>
<tr>
<td>PHF-1</td>
<td>Late-stage neurofibrillary tangles</td>
<td>Monoclonal</td>
<td>Peter Davies</td>
</tr>
<tr>
<td>HT7</td>
<td>Phosphorylated tau</td>
<td>Monoclonal</td>
<td>Pierce Biotechnology</td>
</tr>
<tr>
<td>Ubiquitin</td>
<td>Lewy bodies</td>
<td>Polyclonal</td>
<td>Dako</td>
</tr>
<tr>
<td>z-Synuclein</td>
<td>Lewy bodies</td>
<td>Polyclonal</td>
<td>Chemicon International</td>
</tr>
<tr>
<td>Tau-CCP</td>
<td>Caspase-cleaved fragments</td>
<td>Polyclonal</td>
<td>Troy Rohn, Boise State University, Boise, ID</td>
</tr>
<tr>
<td>TDP-43</td>
<td>TAR DNA binding protein-43</td>
<td>Polyclonal</td>
<td>ProSci Incorporated, Poway, CA</td>
</tr>
<tr>
<td>ApoE</td>
<td>Apolipoprotein E</td>
<td>Polyclonal</td>
<td>Chemicon International</td>
</tr>
</tbody>
</table>

Although there was no history of alcohol abuse or tobacco use, the patient had used cocaine and marijuana occasionally for an unknown period ending in his late 20s. His family history was significant for dementia in both his father, with age of onset of 75 years, and an older brother, also a professional boxer (heavyweight), who died at age 53 years with severe impairment. No neuropathological data were available for these individuals. During the entire 7-year period the patient was being followed clinically, none of his surviving family members, including his mother and 6 siblings, exhibited dementia per his wife, although all reportedly had difficulties with depression. The initial neurological examination was within normal limits, with the exception of bilateral slowing in fine sequential finger movements, and mild difficulties with tandem gait. Additional impairments in gait, including short steps with mild shuffling and a bilateral lack of arm swing, were observed during the last two evaluations, as well as bilateral paramyotonia and bradykinesia, plus a snout reflex.

Neuropsychological evaluations

Scores on 18 tests in the UCI-ADRC neuropsychological battery are reported in Table 3 for each of the patient’s seven visits. At the time of his initial visit, his score of 23/30 points on the Mini-Mental State Examination (MMSE) suggested a mild dementia. Scores on the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) Word List, a test of recent verbal memory, were below average, with impaired performance on measures of delayed free recall, recognition, and the use of organizational strategies. Immediate attention span, as measured by the Wechsler Adult Intelligence Scale-III (WAIS-III) Digit Span test, was also reduced. He was slower than 95% of his peers at processing information in working memory, with severely impaired scores on the Symbol Digit Modality Test, Part A of the Trail-Making Test, and the Kendrick Digit Copy tests. Given the personality changes reported by his wife, it is not surprising that he showed significant deficits on multiple measures of executive functioning, including everyday problem solving (e.g., Social Judgment), abstract reasoning (e.g., WAIS-III Similarities), and mental flexibility (e.g., Part B of the Trail-Making Test). Although verbal comprehension and repetition were unaffected, he showed mild problems on tests of confrontation object naming (e.g., Boston Naming Test), and verbal fluency (e.g., Category and Letter Fluency). Basic constructional abilities, such as copying pictures of different geometric shapes on the CERAD Drawing task, remained preserved except when the task required the use of executive skills such as reasoning, planning, and organization (e.g., WAIS-III Block Design). Over the course of his illness, a slow but progressive deterioration in his scores was observed on almost all neuropsychological measures except for basic drawing ability. At his last visit 7 years following his entry into the UCI-ADRC, and approximately 11 months prior to his death, he was severely demented and unable to perform any of the cognitive

Neuroimaging

Computed tomography (CT) of the head performed 6 years prior to his initial visit revealed a mild degree of central atrophy, slight prominence of the third and lateral ventricles, and a large cavum septum pellucidum. A magnetic resonance imaging (MRI) scan performed during his first visit confirmed the presence of mild diffuse cerebral atrophy, along with nonspecific bilateral periventricular white matter changes. His final MRI scan, performed during his fifth visit, revealed moderate central atrophy and mild generalized cortical atrophy abnormal for his age (Fig. 1A). This MRI also showed thinning of the corpus callosum, mild-to-moderate hippocampal atrophy with the right side being more affected than the left, and mild-to-moderate white matter changes without focal lesions.
tests in the battery. His scores on the MMSE and Severe Impairment Battery (SIB) at that time were 10/30 and 74/100 points, respectively.

**Neuropsychiatric changes**

Table 4 chronicles the patient’s behavioral symptoms as reported annually by his wife on the Neuropsychiatric Inventory (NPI; Cummings et al., 1994). On the NPI, the informant is asked to report the presence or absence of 12 behavioral symptoms during the preceding month. When present, the informant is asked to rate how frequently the behavior occurred on a 4-point scale (i.e., occasionally, often, frequently, or very frequently), as well as its severity using a 3-point scale (i.e., mild, moderate, or severe). Scores reported in Table 4 range from 0–12, and represent the sum of the frequency by severity ratings for each behavior. Overall, the NPI shows a clinical profile suggestive of a frontal syndrome, with the highest scores seen on measures of apathy, depression, disinhibition, agitation, and irritability. Additional symptoms included inappropriate elation, delusions of grandeur, changes in appetite and eating behavior, and repetitive motor activities. More specifically, he showed a childish sense of humor and would laugh at things other people did not find funny, as well as make grandiose comments about himself and his boxing career. In fact, for 5 of the 7 years he was followed, he believed that he was still boxing, and could easily perform the jobs of other professionals (e.g., doctors and lawyers) without any training. He also showed an increased appetite for sweets, resulting in weight gain, and would occasionally put too much food into his mouth. On most visits, his wife also reported that he had problems with excessive fidgeting and an inability to stop a task once started. For example, he would repetitively engage in household activities, such as stacking coins, sweeping the floor, and watering plants. Prior to death, the DP patient suffered recurrent febrile episodes, with the last recorded temperature being 102.2°F. ApoE genotyping was conducted and the DP patient was ApoE3/4.

**Gross pathology and final diagnosis**

At autopsy, the brain weighed 1115.9 g. The cerebral arteries at the base of the brain were free of atherosclerosis and the leptomeningeal vessels appeared normal. In coronal section there was minimal cortical atrophy in the sylvian region.
Before the brain was hemisected, the septum pel-
lucidum was absent, and there was moderately severe ven-
tricular enlargement with thinning of the corpus callosum. An
irregular 0.4-cm infarct was observed within the medial pal-
lidal segment. There was moderate depigmentation in the
substantia nigra (Fig. 1C and E) and the locus ceruleus (Fig.
1C). In the cerebral cortex there was rarefaction that was
prominent in layer 2 of the temporal cortex (Fig. 1D). Lewy
bodies were not observed. As the pathological criteria for
other FTDs were not met, and in consideration of the clinical
details, the final diagnosis was dementia pugilistica.

Grey matter Aβ pathology

Diffuse Aβ plaques visualized by silver staining were
widespread, yet mild-to-moderate neuritic plaques were
distributed in the middle frontal and rostral and caudal cin-
gulate cortices. Neuritic plaques were minimal within the
superior temporal, inferior parietal, and calcarine/peri-
calcarine cortices, and within the hippocampal CA1, sub-
icular, entorhinal-transentorhinal region, and the amygdala.

By immunohistochemistry, the DP patient showed pri-
marily Aβ 1-16 in diffuse plaques and on extracellular NFTs,
compared to the extensive plaque labeling seen in the FTD-AD patient, and in a typical AD case (Fig. 2A–D). Aβ1-16 immunostaining illustrates primarily diffuse plaque and extracellular neurofibrillary tangle (NFT) labeling in the DP case (A) as compared to the extensive plaque labeling seen in the frontotemporal dementia (FTD)-AD case (B), and the typical AD case (C), but is absent in the control case (D). Aβ1-42 immunostaining in the DP case (E), the FTD-AD case (F), the typical AD case (G), and the control (H), was similar to that observed with immunolabeling for Aβ1-16. Less Aβ1-40 immunolabeling was observed in the DP case (I), with deposits being primarily seen within diffuse plaques and on extracellular NFTs. In comparison, Aβ1-40 was observed in plaques in the FTD-AD case (J), and primarily within neuritic plaque cores and associated with blood vessels in the typical AD case (K), and was absent in the control case (L; scale bar = 500 μm). Color image is available online at www.liebertonline.com/neu

**FIG. 2.** Frontal cortical beta-amyloid (Aβ) neuropathology in the dementia pugilistica (DP) case compared to the Alzheimer’s disease (AD) and nondemented control cases. Aβ1-16 immunostaining illustrates primarily diffuse plaque and extracellular neurofibrillary tangle (NFT) labeling in the DP case (A) as compared to the extensive plaque labeling seen in the frontotemporal dementia (FTD)-AD case (B), and the typical AD case (C), but is absent in the control case (D). Aβ1-42 immunostaining in the DP case (E), the FTD-AD case (F), the typical AD case (G), and the control (H), was similar to that observed with immunolabeling for Aβ1-16. Less Aβ1-40 immunolabeling was observed in the DP case (I), with deposits being primarily seen within diffuse plaques and on extracellular NFTs. In comparison, Aβ1-40 was observed in plaques in the FTD-AD case (J), and primarily within neuritic plaque cores and associated with blood vessels in the typical AD case (K), and was absent in the control case (L; scale bar = 500 μm). Color image is available online at www.liebertonline.com/neu

compared to the extensive plaque labeling seen in the FTD-AD patient, and in a typical AD case (Fig. 2A–D). Aβ1-42 immunostaining in the DP case, the FTD-AD case, the typical AD case, and the control (H) were similar to that observed with immunolabeling for Aβ1-16 (Fig. 2E–H). Less Aβ1-40 immunolabeling was observed in the DP case, with deposits being primarily seen within diffuse plaques and on extracellular NFTs (Fig. 2I–L). In comparison, Aβ1-40 was observed in plaques in the FTD-AD case, primarily within neuritic plaque cores and associated with blood vessels in the typical AD case (Fig. 2K). Numerous extracellular tangles were positive for Aβ (Fig. 3A–C). In addition, particularly for Aβ1-40, there were small punctuate deposits in the vicinity of Aβ-positive NFTs (Fig. 3C), that were subsequently determined to be localized within microglial cells that were positive for HLA-DR (Fig. 3D–I).

**Grey matter tau pathology in the frontal cortex**

NFTs were extensive within the frontal, temporal, and parietal neocortices, and within the CA1, subiculum, and the entorhinal-transentorhinal region. NFTs were also observed within the midbrain tegmentum, substantia nigra, pontine tegmentum, locus ceruleus (Fig. 1F), and medullary tegmentum, and in scattered distribution within the striatum, globus pallidus, and thalamus. Extracellular NFTs were prominent, particularly where intracellular NFT formation was heavy. Using a battery of markers representing different phosphorylation states of tau that may indicate disease progression (Augustinack et al., 2002), we observed differences in the distribution and extent of different phosphorylated tau species compared to the other cases (Fig. 4). First, MC-1 labeling specific for a folded conformation of tau (Jicha et al., 1997), which is also thought to represent early NFT formation (Uboga and Price, 2000) appears in scattered neurons, whereas in the AD cases, it is also distributed within dystrophic neurites associated with plaques (Fig. 4A–D). Interestingly, AT8-positive neurons containing tau phosphorylated at S199/S202/T205, also thought to be an early event in NFT formation (Su et al., 1994), were similar in extent and distribution in the DP case compared to the AD cases. However, AD patients with clinical signs of frontal lobe dysfunction showed more extensive AT8 labeling (Fig. 4E–H). Lastly, there was a differential distribution of PHF-1, reflecting mature NFT formation and abnormal phosphorylation at
Ser396/Ser404 (Otvos et al., 1994), with immunostaining prominent in layer 2 in the DP case, compared to the AD cases (Newman et al., 2005; Fig. 4I–L). This pattern in the DP case was similar to that previously reported (Hof et al., 1992). For all antibodies against phosphorylated tau, we observed neuropil threads in all cases examined, but not in controls.

We next determined whether caspase activation had occurred in NFT-bearing neurons, as has been reported in AD, which may be an early event contributing to NFT formation (Newman et al., 2005; Rohn and Head, 2008). We observed a significant presence of tau-caspase cleavage product (tau-CCP) in NFT-bearing neurons in the DP case, in association with extracellular NFTs (Fig. 5A–F). As in the AD cases, neuropil threads in the DP case also contained tau-CCP. The only distinguishing feature in the DP case was the lack of plaque-associated tau-CCP-positive dystrophic neurites.

Grey matter TDP-43 pathology in the frontal cortex

Immunostaining for TDP-43 in the frontal cortex of our DP case revealed fibrils, dense granules, NFT labeling, and coiled body-like comma-shaped TDP-43-positive oligodendrocytes (Brandmeir et al., 2008; Fig. 5G–J).

*Grey matter glial cell activation, complement, ApoE, and APP in the frontal cortex*

In acute brain injury there is evidence that inflammation may be a priming event for the future development of AD (Griffin et al., 1994). We used several markers to detect inflammation in our DP case, for purposes of comparison with the AD cases (Fig. 6). Despite the small numbers of neuritic Aβ deposits, we observed significant GFAP protein labeling in the DP case, with morphology consistent with hypertrophied astrocytes (Fig. 6A–D), although the extent and intensity was less than that seen in the AD cases. HLA-DR-positive microglial cells were also detected, although less extensively than those observed in the AD cases (Fig. 6E–H). The intensity of astrocytosis and of microglial cell labeling with HLA-DR was higher in all AD cases and lowest or absent in controls. We have previously shown that complement activation on neurons may contribute to neuron loss in the hippocampus in a patient with relapsing polychondritis (Head et al., 2009).
et al., 2006). We hypothesized that complement may also be upregulated in DP, despite the limited numbers of neuritic plaques observed. Complement proteins were observed in the frontal cortex, at intensities similar to those seen in the AD cases (Fig. 6I–L). However, in the AD cases C1q was associated with Aβ deposition and NFT-bearing neurons, whereas in the DP case C1q labeling was limited to neurons (Fig. 7A). Furthermore, in our DP case, non-NFT-bearing neurons as well as extracellular NFTs contained C1q (Fig. 7A). Apolipoprotein E (ApoE) is also thought to mediate the neuropathology of repetitive head trauma (Jordan et al., 1995), and of traumatic brain injury (DeKosky et al., 2007), and we observed ApoE labeling within extracellular NFTs in the DP case (Fig. 7A). ApoE immunolabeling also revealed positive blood vessels, but most appeared to be morphologically normal. C1q was found in association with a subset of blood vessels and within glial cells in proximity to blood vessels (Fig. 8B). In other areas of the frontal white matter, there appeared to be extravasation of C1q in clouds in the vicinity of unlabeled blood vessels in our DP case.

Markers for NFT pathology in the white matter also revealed some interesting differences between DP and AD. Using MC-1, our patient showed punctate white matter deposits that included scattered coiled bodies, representing oligodendrocyte tau inclusions (Fig. 8C) and fibers (Fig. 8D). Interestingly, AT8 labeling was negative in the white matter of our patient, but presented as threads or fibers in the AD cases. Lastly, HT7 labeling, which recognizes tau independently of phosphorylation state, showed

**FIG. 4.** Patterns of tau immunostaining in the frontal cortex of the patient with dementia pugilistica (DP), compared to Alzheimer’s disease (AD) and nondemented cases. MC-1 immunolabeling of phosphorylated tau revealed neuronal labeling in the DP case (A), plaque-associated neuritic labeling in the frontotemporal dementia (FTD)-AD case (B), a mix of neurofibrillary tangles (NFTs) and dystrophic neurites in the typical AD case (C), but absent in the control case (D). AT8 immunoreactivity also was limited to intracellular NFTs in the DP case (E), and within NFTs and plaque-associated dystrophic neurites in the FTD-AD case (F) and the typical AD case (G), but were not present in the control case (H). PHF-1 immunostaining was the most extensive of the three pathological tau markers, and showed significant intracellular and extracellular NFT labeling in the DP case (I), and within NFTs and plaque-associated dystrophic neurites in the FTD-AD case (J), but was less extensive and limited to NFTs in the typical AD case (K). No PHF-1-positive tangles were observed in the control case (L; scale bar = 100 μm). Color image is available online at www.liebertonline.com/neu
dark and intense punctuate labeling in the white matter of the DP case (Fig. 8E), and was associated with fibers (Fig. 8F). Thus in our patient there was evidence for glial tangles and coiled bodies in the white matter that were positive for both phosphorylated tau and nonphosphorylated tau, consistent with other reports of autopsy cases with FTLD (Cairns et al., 2007a; McKhann et al., 2001). However, overall these tau-positive deposits were relatively rare in the DP case.

Hippocampal pathology

As in the frontal cortex, Aβ plaques were primarily of the diffuse type (Fig. 9A) in DP, whereas a mixture of diffuse, mature, and neuritic plaques was seen in the AD cases (data not shown). Extensive HLA-DR-positive microglial cells were seen in all subfields of the hippocampus in the DP case (Fig. 9B). Neuronal and extracellular NFT labeling for C1q was observed in the hippocampus (Fig. 9C), whereas the

FIG. 5. Caspase activation and TDP-43 in dementia pugilistica (DP). (A–F) Tau-caspase cleavage product (green) was present within a subset of PHF-1 positive tangles (red). TDP-43 was observed within dystrophic neurites (G), intracellular inclusions (H), extracellular neurofibrillary tangles (NFTs) (I), and within oligodendroglial cells (J; scale bar = 10 μm). Color image is available online at www.liebertonline.com/neu
distribution in AD was seen predominantly in association with plaques. Neurons within the DP hippocampus were positive for tau-CCP (data not shown). TDP-43 immunolabeling revealed the presence of dystrophic neurites (Fig. 9D), and of clusters of shorter dystrophic neurites with swollen nerve terminals (Fig. 9E). Thus, as in the frontal cortex, DP was associated with diffuse plaques, extracellular NFTs, and extensive intracellular NFT formation, along with evidence of neuroinflammation.

Discussion

We describe the clinical and neuropathological features of a patient with DP who presented with clinical signs predominantly localizable to the frontal lobe. At autopsy, we observed neuropathology that overlapped with both AD and with FTLD. Aβ deposition was primarily seen within diffuse plaques and associated with extracellular NFTs. In contrast, the distribution of NFTs within subcortical nuclei and within white matter glial inclusions was similar to some FTLD cases. Further, tau protein accumulating within neurons of the DP brain had undergone caspase cleavage. Elevation in neuroinflammation was a major component of the neuropathology of DP, along with an accumulation of APP on white matter blood vessels, that has not been reported previously.

The patient’s neuropsychological and behavioral symptoms support a diagnosis of FTD, although many of the clinical features may be present in other forms of dementia. Neary and associates identified the core diagnostic features of FTLD as early (1) decline in social interpersonal conduct, (2) impairment in the regulation of personal conduct, (3) emotional blunting, and (4) loss of insight (Neary et al., 1998). At the time of his initial evaluation, our patient exhibited all four of these symptoms. The most noticeable early cognitive deficits in FTD occur in executive functioning rather than recent memory. Although delayed recall and recognition, as measured by the CERAD Word List, were significantly impaired, our patient’s scores were higher than those typically seen in AD patients. The fact that our patient’s scores on tests of executive functioning, such as insight, reasoning (e.g., Social Judgment and Similarities), mental flexibility (e.g., Trail-Making Test), and concentration (e.g., Digit Span and Symbol
FIG. 7. Neuronal C1q and apolipoprotein E (ApoE) labeling in the frontal cortex of the dementia pugilistica (DP) case. (A) C1q-positive neurons were observed on extracellular neurofibrillary tangles (NFTs), as was (B) ApoE labeling (scale bar = 20 μm). Color image is available online at www.liebertonline.com/neu.

FIG. 8. Frontal white matter pathology in dementia pugilistica (DP). (A) HLA-DR-positive microglial cells and macrophages (arrows) were observed in clusters. (B) C1q labeled a subset of blood vessels in addition to adjacent glial cells (arrow). MC-1 positive punctate white matter deposits were observed, as well as rare oligodendrogial positive inclusions (arrow in C), and fiber labeling (arrow in D). HT7 labeling, indicating total tau, was increased in the DP case, and associated with glial tangles (arrow in E), and fibers (F; scale bar = 20 μm). Color image is available online at www.liebertonline.com/neu.
Digit Modality Test), were disproportionately impaired was more similar to FTD.

The most striking neuropathological feature in this case was extensive NFT pathology, affecting cortical regions and brainstem nuclei as reported previously (Areza-Fegyveres et al., 2007). The presence of motor dysfunction in DP may reflect NFT pathology compromising frontal circuits and brainstem motor systems. Further, the distribution of NFT pathology in our patient, relative to other AD cases and to frontal AD cases, is consistent with a previous report in a 58-year-old boxer (Hof et al., 1992), in whom NFTs were more frequently found in superficial layers of the cortex associated with corticocortical pathways. Thus, although there is significant NFT pathology in DP, the distribution of tangles can distinguish these cases from AD (i.e., superficial cortical layer involvement, brainstem NFTs, and white matter glial tangles; Hof et al., 1992).

White matter degeneration has been reported previously in DP, including a loss of myelin and gliosis (Corsellis et al., 1973). Distorted end swellings and reduction of axons in white matter have also been noted (Lampert and Hardman, 1984). There are few reports of glial tangles in DP. Ikeda and colleagues observed thorn-shaped astrocytes, but not tuft-shaped astrocytes or coiled bodies (Ikeda et al., 1998). Schmidt and colleagues observed glial (astrocyte) NFTs in neocortical white and gray matter, as well as in the brainstem and spinal cord (Schmidt et al., 2001). In the current case study, we observed glial NFTs and coiled bodies, which are frequently found in corticobasal degeneration and progressive supranuclear palsy (Ikeda et al., 1998). Interestingly, these two diseases are characterized by extrapyramidal motor signs and subcortical tangles (Belfor et al., 2006; Kumar-Singh and Van Broeckhoven, 2007). Motor signs in our patient may thus be associated with white matter glial NFTs and subcortical NFTs, as reported in other case studies (Corsellis et al., 1973).

The extent of Aβ deposition in previous case reports is variable and may reflect differences in detection techniques (e.g., silver stains versus immunohistochemistry), and in the ages of the patients at autopsy. The presence of diffuse plaques is consistent with several previous reports (Areza-Fegyveres et al., 2007; Roberts, 1988; Schmidt et al., 2001; Tokuda et al., 1991), although other studies report no plaque pathology (Geddes et al., 1999; Hof et al., 1992). Typically, Aβ deposition in diffuse plaques has not been reported in young boxers despite the presence of tau accumulation (Geddes et al., 1999). In a transgenic mouse model of AD (Tg2576), repetitive mild brain injury in 9-month-old animals (pre-Aβ deposition) accelerated Aβ plaque pathology and induced cognitive impairments (Uryu et al., 2002). Interestingly, no motor impairments were observed, which may be due to a lack of NFT pathology, which contrasts with a report in a tauopathy mouse model (Yoshiyama et al., 2005). The most distinguishing feature of the Aβ pathology in this case was that of extracellular NFTs, as reported previously (Allsop et al., 1990; Hof et al., 1992; Tokuda et al., 1991). We further characterized extracellular NFT pathology and showed that both Aβ1-40 and Aβ1-42 are involved. The source of extracellular NFT-associated Aβ is difficult to determine, but morphologically appears to be derived from disrupted neuronal membranes. Also, the presence of an ApoE4 allele (our patient was ApoE3/4), may also have contributed to the level of Aβ pathology (Jellinger, 2004; Jordan et al., 1995, 1997).

We tested whether significant cerebrovascular damage would be present in our patient given previous reports in younger boxers and in TBI patients (Jordan, 2000).
Interestingly, in a report of one 23-year-old boxer, NFTs were distributed in a perivascular pattern, suggesting a possible link between vascular compromise and neurodegeneration (Geddes et al., 1999). We observed little cerebral amyloid angiopathy in the current case, which is consistent with a previous study (Tokuda et al., 1991). However, we did find increased amyloid precursor protein (APP) immunolabeling in large blood vessels within the frontal cortex white matter that was substantially different from the AD and control cases. Increased vascular APP may be consistent with reports of neuronal overexpression of APP and associated increases in IL-1β-positive activated microglial cells in head injury cases (Griffin et al., 1994). Targeting IL-1 has been proposed as a potential therapy for TBI, and the IL-1 receptor antagonist (IL-1ra) that can attenuate IL-1 signaling is well tolerated by rheumatoid arthritis patients (Lucas et al., 2006). Intraventricular delivery of antibodies against IL-1α or IL-1β significantly attenuated TBI-induced neuronal loss in Sprague-Dawley rats (Lu et al., 2005). Whether increased vascular APP reflects a compensatory response or an injury response in our patient is difficult to determine.

Additional observations we provide in the current case study include evidence for neuroinflammation, caspase activation, the presence of aberrant cellular localization of TDP-43 (also recently reported by King et al., 2010), and further evidence of white matter pathology. Many of these features appear to be more similar to those observed in FTLD, which may account for the primarily frontal syndrome observed in the clinic. We observed large numbers of HLA-DR-positive microglial cells within the frontal cortex and hippocampus, despite the lack of significant neuritic plaque accumulation. Similar microglial activation has been described in FTLD, both by in vivo imaging (Cagnin et al., 2004), and by immunohistochemistry (Arnold et al., 2000; Schofield et al., 2003). Microglial cell activation may result in the release of proinflammatory cytokines and chemokines and exacerbate neuronal dysfunction (Lucas et al., 2006; Nguyen et al., 2002).

As a second marker for upregulation of the inflammatory cascade, we immunostained the brain of the DP case with anti-C1q antibodies. The complement (C) system is critically involved with humoral and cellular immunity and inflammatory responses, and has been implicated in several neurodegenerative diseases (van Beeck et al., 2003). C1q was primarily neuronal in our case and seen on extracellular NFTs, in contrast to both neuronal- and plaque-associated C1q in the AD cases (Afagh et al., 1996; Fonseca et al., 2004). This may suggest that C1q may be increased in DP in response to the disruption of NFT-bearing neuronal membranes that may stimulate an immune response. A role for Aβ accumulation on extracellular NFTs as another C1q activator is also possible, because in AD, fibrillary forms of Aβ can bind and activate C1, the first component of the classical C′ pathway (Jiang, 1994; McGeer and Rogers, 1992; Webster, 1997). Complement-mediated generation of proinflammatory factors can initiate or induce the recruitment and activation of glial cells, which in turn may contribute to neuronal degeneration. Consistent with this hypothesis is the observation of HLA-DR-positive microglial cells containing Aβ in the vicinity of Aβ-positive extracellular NFTs.

Caspase activation detected as caspase-cleaved fragments of tau (tau-CCP) may suggest that activation of apoptosis pathways may mediate cell death in DP, as has been reported for other tauopathies (Gamin et al., 2003; Newman et al., 2005; Rissman et al., 2004). We extend previous reports of the accumulation of tau-CCP and a possible role in DP-associated neurodegeneration. We observed significant tau-CCP immunostaining in both the frontal cortex and hippocampus of our patient. Tau-CCP was preferentially distributed within NFT-bearing neurons, but was also observed on extracellular NFTs. In contrast to DP, and as reported previously, tau-CCP was present in both NFT-bearing neurons and in dystrophic neurites associated with plaques in AD cases (Gamin et al., 2003; Rissman et al., 2004). Tau-CCP has been proposed as a possible link between Aβ and tau pathology; caspase activation may be initiated by exposure to Aβ, and lead to the cleavage of tau protein, thus accelerating the production of NFT in AD (de Calignon et al., 2010; Gamin et al., 2003; Hyman, 2011; Rissman et al., 2004). However, in vivo imaging of both caspase activation and NFT formation in mouse brain suggests that although these two events are linked, there is no evidence for TUNEL labeling or nuclear fragmentation in these NFT-bearing neurons (Spires-Jones et al., 2008), arguing against full engagement of apoptosis. Interestingly, intracerebroventricular injection of a pan-caspase inhibitor in rodents reduced TBI-induced increases in caspase-3 activation, improved histological outcomes, and attenuated Aβ accumulation in the central nervous system (CNS; Abrahamson et al., 2006).

A novel proteinopathy described in FTLD and in amyotrophic lateral sclerosis (ALS) is the mislocalization of TDP-43 (Cairns et al., 2007b; Gitcho et al., 2008; Neumann et al., 2006). In FTLD with ubiquitin-immunostained-positive inclusions, TDP-43 is observed as cytoplasmic inclusions, dystrophic neuritis, and intranuclear inclusions (Armstrong et al., 2010; Neumann et al., 2006). The intensity of normal nuclear TDP-43 is reduced in FTLD with ubiquitin inclusions, suggesting mislocalization and aggregation (Forman et al., 2007). We hypothesized that TDP-43 proteinopathy may also contribute to DP. Immunostaining for TDP-43 in DP showed similar levels of nuclear immunoreactivity to those of controls, but with rare dystrophic neurites. Cytoplasmic aggregates may also be present within fragmented nuclei. There was little evidence of nuclear inclusion formation, which suggests a distribution similar to either a subtype 1 or 2 (Forman et al., 2007; Kwong et al., 2007). A small number of extracellular tangles were positive for TDP-43. Thus TDP-43 pathology was present in the current DP case as described previously (King et al., 2010), but with far lower frequency than those described previously for FTLD and ALS.

A prime candidate for the spread of tau pathology in CTE is via a transcellular or prion-like mechanism (Aguzzi and Rajendran, 2009; Clavaguera et al., 2009; Frost and Diamond, 2010; Frost et al., 2009; Goedert et al., 2010). Recently there has been considerable emphasis on the transmission or propagation of protein misfolding or proteinopathies in several neurodegenerative diseases, and indications that the mechanism may have similarities to those that underlie prion pathogenesis (Angot et al., 2010; Brundin et al., 2008; Clavaguera et al., 2009; Frost and Diamond, 2010; Goedert et al., 2010; Li et al., 2008; Meyer-Luehmann et al., 2006; Morales et al., 2011; Volpicelli-Daley et al., 2011). Like classical prion disorders, there is some evidence that the source of the nucleating agent and the host can affect the onset and type of neuropathology (Meyer-Luehmann et al., 2006), and that soluble prionoid forms can also induce amyloidogenesis in the CNS (Langer
et al., 2011). For example, neuropathological changes in Parkinson’s disease (PD) progress slowly and spread according to a characteristic pattern (Kordower et al., 2008, 2011; Li et al., 2008). Two of these studies demonstrate that grafted healthy neurons can gradually develop the same pathology as host neurons in the diseased brains (Brundin et al., 2008, Kordower et al., 2008; Li et al., 2008). The latest studies with α-synuclein (Volpicelli-Daley et al., 2011) or Aβ aggregates (Morales et al., 2011) have established that transgenic animal models over-expressing human mutant forms of neuronal proteins are not required to show prion-like behavior, because in these two studies wild-type mice inoculated with misfolded forms of α-synuclein or Aβ that would never develop spontaneous proteinopathies or parenchymal prionoid deposits developed neuropathological changes in the CNS.

Recently, there has been considerable interest in CTBI and CTE in other sports, such as American football, wrestling, hockey, lacrosse, and even soccer (DeKosky et al., 2010; Matser et al., 1999, 2001; McKee et al., 2009). While the exact mechanisms involved in the significant long-term delayed sequelae associated with sports-related CTE are poorly understood (DeKosky et al., 2010), the clinical presentation appears to be due to a slowly-progressive tauopathy (McKee et al., 2009). Currently there is an urgent need for better animal models of mild repetitive TBI that replicate the pathogenesis of CTE, so that the cellular and molecular changes that contribute to the propagation of tau pathology can be delineated, and effective therapies can be developed and deployed long before the onset of neurocognitive deficits. Another critical area is the identification of biomarkers that can be used to predict which individuals are at the greatest risk of developing CTE, as well as to provide feedback about the efficacy of future therapeutic interventions.

Acknowledgments

Funding supported by the University of California Irvine Alzheimer’s Disease Research Center (National Institutes on Health/National Institutes on Aging Grant #P50 AG16573), National Institutes on Health/National Institutes on Aging Grant #AG21912, and #AG00538. Additional support was received from the University of Kentucky Alzheimer’s Disease Center Grant #P30 AG028383. A subset of human tissues was obtained from the National Institute of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders under contracts N01-HD-4-3368 and N01-HD-4-3383. We are grateful to the family and to our patient with DP for their contributions to the study.

Author Disclosure Statement

No competing financial interests exist.

References


King, A., Sweeney, F., Bodi, I., Troakes, C., Maekawa, S., and Al-Sarraj, S. (2010). Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer’s disease. Neuropathology 30, 408–419.


Li, J.Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P., Rehncrona, S., Bjorklund, A., Wid-


Address correspondence to:
Elizabeth Head, Ph.D.
Associate Professor
Sanders-Brown Center on Aging
203 Sanders-Brown Building
800 South Limestone Street
Lexington, KY, 40536
E-mail: Elizabeth.head@uky.edu